Design and Challenges of the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy (RENAL) Trial: High-Dose versus Standard-Dose Hemofiltration in Acute Renal Failure
| Autor: | Wim Van Biesen, Aiwu Lin, Jung Woo Shin, Yue Gu, Maria Alquist, Pascal Verdonck, Hugh Feidhlim Woods, Jae Cheol Hwang, Dong Min Kim, Sunny Eloot, Jonas Axelsson, Jiaqi Qian, Maengseok Noh, Min-Woo Jo, Sylvie Dusilová-Sulková, Li-Jun Tang, Chen Ting Cheng, Ji-Hong Yang, Bengt Lindholm, Vladimír Polakovič, R. T. Noel Gibney, M. Bengt Lindholm, Annemieke Dhondt, Martin Válek, Tao Wang, Raymond Vanholder, František Lopot, Na Jiang, Qiang Yao, Po Sung Lim, Jongha Park, Erik Billiet, Juan P. Bosch, Colin F. Johnston, Hyun Chul Chung, D.J. Kutsogiannis, S.M. Bagshaw, Jong Soo Lee, Li-Tao Cheng, Byeong Man Lee |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Nephrology
medicine.medical_specialty medicine.medical_treatment Hemodiafiltration urologic and male genital diseases Continuous hemodiafiltration Internal medicine Intensive care Hemofiltration medicine Humans Renal replacement therapy Intensive care medicine Dialysis Randomized Controlled Trials as Topic Kidney business.industry Australia Hematology General Medicine Acute Kidney Injury female genital diseases and pregnancy complications medicine.anatomical_structure business New Zealand |
| Zdroj: | Blood Purification. 26:407-416 |
| ISSN: | 1421-9735 0253-5068 |
| DOI: | 10.1159/000148400 |
| Popis: | Background/Aims: The optimal dose of renal replacement therapy (RRT) in acute renal failure (ARF) is uncertain. Methods: The Randomized Evaluation of Normal versus Augmented Level Replacement Therapy Trial tests the hypothesis that higher dose continuous veno-venous hemodiafiltration (CVVHDF) at an effluent rate of 40 ml/kg/h will increase survival compared to CVVHDF at 25 ml/kg/h of effluent dose. Results: This trial is currently randomizing critically ill patients in 35 intensive care units in Australia and New Zealand with a planned sample size of 1,500 patients. This trial will be the largest trial ever conducted on acute blood purification in critically ill patients. Conclusion: A trial of this magnitude and with demanding technical requirements poses design difficulties and challenges in the logistics, conduct, data collection, data analysis and monitoring. Our report will assist in the development of future trials of blood purification in intensive care. This study was registered with ClinicalTrials.gov (NCT00221013). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|